Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19

Peter Nordbeck^{1

2}, Kai Hu^{1

2}

Affiliations

¹ Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; and.
² Comprehensive Heart Failure Center, Würzburg, Germany.

Comment

Peter Nordbeck et al. J Cardiovasc Pharmacol. 2020 Aug.

. 2020 Aug;76(2):123-124.

doi: 10.1097/FJC.0000000000000875.

Peter Nordbeck^{1

2}, Kai Hu^{1

2}

¹ Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; and.
² Comprehensive Heart Failure Center, Würzburg, Germany.

No abstract available

Comment on

Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications.
Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, Galante D, Golino P, Nigro G. Russo V, et al. J Cardiovasc Pharmacol. 2020 Aug;76(2):138-145. doi: 10.1097/FJC.0000000000000854. J Cardiovasc Pharmacol. 2020. PMID: 32453074 Review.

1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
1. Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:E2582.
1. Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440.
1. Russo V, Rago A, Carbone A, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological implications. J Cardiovasc Pharmacol. 2020 May 18. doi: 10.1097/FJC.0000000000000854. Online ahead of print.
1. Buckely LF, Cheng JWM, Desai A, et al. Cardiovascular pharmacology in the time of COVID-19: a focus on angiotensin converting enzyme. J Cardiovasc Pharmacol. 2020;75:526–529.